{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:19:29Z","timestamp":1790867969318,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-20-130-01-DDC"],"award-info":[{"award-number":["RSG-20-130-01-DDC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"publisher","award":["P30CA068485"],"award-info":[{"award-number":["P30CA068485"]}],"id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["R01 CA227833"],"award-info":[{"award-number":["R01 CA227833"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["T32 DK101003"],"award-info":[{"award-number":["T32 DK101003"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["R01 DA046138"],"award-info":[{"award-number":["R01 DA046138"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["R00 CA256350"],"award-info":[{"award-number":["R00 CA256350"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["F31 CA290735"],"award-info":[{"award-number":["F31 CA290735"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["R01 LM013434"],"award-info":[{"award-number":["R01 LM013434"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM146987"],"award-info":[{"award-number":["R35GM146987"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007208","name":"Vanderbilt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA248505"],"award-info":[{"award-number":["R01CA248505"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218607","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:36:31Z","timestamp":1779464191000},"page":"218607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan"],"prefix":"10.1016","volume":"654","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9967-5398","authenticated-orcid":false,"given":"Sarah J.","family":"Harmych","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-9180","authenticated-orcid":false,"given":"Hidenori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Bogatcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-8559","authenticated-orcid":false,"given":"Marisol A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Graves-Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2117-1162","authenticated-orcid":false,"given":"Claiborne W.","family":"Tydings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2599-8422","authenticated-orcid":false,"given":"Marina T.","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6455-1972","authenticated-orcid":false,"given":"Hunter R Lischwe","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6613-8386","authenticated-orcid":false,"given":"Isabella M.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9858-2637","authenticated-orcid":false,"given":"Khaw","family":"Ti Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0811-1003","authenticated-orcid":false,"given":"Claudia C.","family":"Wahoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-753X","authenticated-orcid":false,"given":"Chelsie K.","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-7998","authenticated-orcid":false,"given":"James N.","family":"Higginbotham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Johnson","family":"Irudayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Revetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7111-4449","authenticated-orcid":false,"given":"Jeffrey L.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyam","family":"Yilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina M.","family":"O'Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatina","family":"Fragkogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5382-0481","authenticated-orcid":false,"given":"Metamia","family":"Ciampricotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Kay","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-6361","authenticated-orcid":false,"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-7232","authenticated-orcid":false,"given":"Allison S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Meiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-9375","authenticated-orcid":false,"given":"Krishna C.","family":"Mudumbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eben","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1357-2158","authenticated-orcid":false,"given":"Bhuminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218607_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218607_bib2","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218607_bib3","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.canlet.2026.218607_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5141","article-title":"Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics","volume":"33","author":"Tydings","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.canlet.2026.218607_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5732\/cjc.010.10542","article-title":"Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations","volume":"30","author":"Wykosky","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218607_bib8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/pharmrev.123.000906","article-title":"Targeting epidermal growth factor receptor for cancer treatment: abolishing both kinase-dependent and kinase-independent functions of the receptor","volume":"75","author":"Zhang","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.canlet.2026.218607_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd1445","article-title":"Cetuximab","volume":"3","author":"Graham","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218607_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2008.07.006","article-title":"The biological properties of cetuximab","volume":"68","author":"Vincenzi","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2026.218607_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218607_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01518458","article-title":"Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma","volume":"37","author":"Naramura","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218607_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"Bardelli","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib15","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","article-title":"Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218607_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00018-023-05071-5","article-title":"Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer","volume":"81","author":"Jones","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2026.218607_bib17","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","article-title":"Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer","volume":"21","author":"Arena","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2159-8290.CD-17-1009","article-title":"Genomic landscape of cell-free DNA in patients with colorectal cancer","volume":"8","author":"Strickler","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218607_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/15384047.2020.1798695","article-title":"Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy","volume":"21","author":"Price","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2026.218607_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4161\/cbt.26340","article-title":"The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies","volume":"14","author":"Esposito","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2026.218607_bib22","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.18632\/oncotarget.26663","article-title":"Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer","volume":"10","author":"Graves-Deal","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218607_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nm.4424","article-title":"LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt\/\u03b2-catenin signaling","volume":"23","author":"Lu","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib24","first-page":"E2852","article-title":"Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218607_bib25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1535-7163.MCT-14-0772","article-title":"Enhanced targeting of the EGFR network with MM-151, an oligoclonal Anti-EGFR antibody therapeutic","volume":"14","author":"Kearns","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218607_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5640","article-title":"MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations","volume":"8","author":"Arena","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02634191","article-title":"Characterization of the DiFi Rectal carcinoma cell line derived from a familial adenomatous polyposis patient","volume":"29","author":"Olive","year":"1993","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.canlet.2026.218607_bib28","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.celrep.2017.04.048","article-title":"A chimeric egfr protein reporter Mouse reveals egfr localization and trafficking in vivo","volume":"19","author":"Yang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218607_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41589-025-02076-y","article-title":"Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap","volume":"22","author":"Lin","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218607_bib30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31993","article-title":"EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo","volume":"6","author":"Pinilla-Macua","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2026.218607_bib31","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3390\/ijms17081200","article-title":"Non-Ligand-Induced dimerization is sufficient to initiate the signalling and endocytosis of EGF receptor","volume":"17","author":"Kourouniotis","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218607_bib32","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/MCB.01809-07","article-title":"A tale of two cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation","volume":"28","author":"Pennock","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218607_bib33","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1091\/mbc.e06-09-0802","article-title":"Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression","volume":"18","author":"Liao","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2026.218607_bib34","doi-asserted-by":"crossref","first-page":"35000","DOI":"10.1074\/jbc.273.52.35000","article-title":"Endocytosis of functional epidermal growth factor receptor-green Fluorescent Protein chimera","volume":"273","author":"Carter","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218607_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-Response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218607_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163366","article-title":"The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance","volume":"11","author":"Sickmier","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218607_bib37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1535-7163.MCT-17-0575","article-title":"Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance","volume":"17","author":"Bagchi","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218607_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008103","article-title":"Efficient consideration of coordinated water molecules improves computational protein-protein and protein-ligand docking discrimination","volume":"16","author":"Pavlovicz","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.canlet.2026.218607_bib39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10822-019-00223-x","article-title":"Blinded prediction of protein\u2013ligand binding affinity using Amber thermodynamic integration for the 2018 D3R grand challenge 4","volume":"33","author":"Zou","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.canlet.2026.218607_bib40","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.canlet.2026.218607_bib41","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.canlet.2026.218607_bib42","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.21105\/joss.06934","article-title":"Alchemlyb: the simple alchemistry library","volume":"9","author":"Wu","year":"2024","journal-title":"JOSS"},{"key":"10.1016\/j.canlet.2026.218607_bib43","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v5.29254","article-title":"Identification and characterization of EGF receptor in individual exosomes by fluorescence\u2010activated vesicle sorting","volume":"5","author":"Higginbotham","year":"2016","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2026.218607_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"10.1016\/j.canlet.2026.218607_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2026.218607_bib46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2026.218607_bib47","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"key":"10.1016\/j.canlet.2026.218607_bib48","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2026.218607_bib49","doi-asserted-by":"crossref","first-page":"W130","DOI":"10.1093\/nar\/gkx356","article-title":"WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218607_bib50","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218607_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113603","article-title":"Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranes","volume":"43","author":"Mudumbi","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218607_bib52","article-title":"Inc","author":"Tempus","year":"2024","journal-title":"Tempus xT Validat. Summary"},{"key":"10.1016\/j.canlet.2026.218607_bib53","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218607_bib54","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218607_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","article-title":"Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA","volume":"5","author":"Finkle","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib57","article-title":"Longitudinal shifts of solid tumor and liquid biopsy sequencing concordance in metastatic breast cancer","volume":"6","author":"Liu","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib58","series-title":"Ggplot2: Elegant Graphics for Data Analysis Using the Grammar of Graphics","author":"Wickham","year":"2016"},{"key":"10.1016\/j.canlet.2026.218607_bib59","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/11205090-000000000-00000","article-title":"Panitumumab: a review of its use in metastatic colorectal cancer","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218607_bib60","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1007\/s12325-021-01809-4","article-title":"Panitumumab: a review of clinical pharmacokinetic and pharmacology properties after over a decade of experience in patients with solid tumors","volume":"38","author":"Kast","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.canlet.2026.218607_bib61","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-Induced anaphylaxis and IgE specific for Galactose- \u03b1-1,3-Galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib62","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2019.00849","article-title":"Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors","volume":"9","author":"Garc\u00eda-Foncillas","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6428","article-title":"Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib64","article-title":"Spatially resolved transcriptomics revealed local invasion-related genes in colorectal cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188165","article-title":"The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression","volume":"135","author":"Thatte","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218607_bib66","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0006-2952(98)00356-6","article-title":"Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)","volume":"57","author":"Discafani","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218607_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13402-016-0270-z","article-title":"Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker","volume":"39","author":"Silva-Oliveira","year":"2016","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib68","doi-asserted-by":"crossref","first-page":"53288","DOI":"10.18632\/oncotarget.18395","article-title":"AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors","volume":"8","author":"Silva-Oliveira","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218607_bib69","doi-asserted-by":"crossref","first-page":"12035","DOI":"10.18632\/oncotarget.3574","article-title":"Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer","volume":"6","author":"Braig","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218607_bib70","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0092-8674(87)90592-7","article-title":"Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells","volume":"51","author":"Di Fiore","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218607_bib71","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.canlet.2026.218607_bib72","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB family in cancer: couples therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218607_bib73","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.1158\/1078-0432.CCR-05-0926","article-title":"Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors May be linked to mutation of ERBB2 rather than EGFR","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00226","article-title":"Validation of HER2 amplification as a predictive biomarker for anti\u2013epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"3","author":"Raghav","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib75","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib76","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218607_bib77","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s42003-025-08699-0","article-title":"3D collagen high-throughput screen identifies drugs that induce epithelial polarity and enhance chemotherapy response in colorectal cancer","volume":"8","author":"Harmych","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218607_bib78","doi-asserted-by":"crossref","first-page":"15968","DOI":"10.18632\/oncotarget.24641","article-title":"Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer","volume":"9","author":"Piulats","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218607_bib79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/intbio\/zyab009","article-title":"Cell surface integrin \u03b15\u00df1 clustering negatively regulates receptor tyrosine kinase signaling in colorectal cancer cells via glycogen synthase kinase 3","volume":"13","author":"Starchenko","year":"2021","journal-title":"Integr. Biol."},{"key":"10.1016\/j.canlet.2026.218607_bib80","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1091\/mbc.e16-12-0852","article-title":"Clustering of integrin \u03b15 at the lateral membrane restores epithelial polarity in invasive colorectal cancer cells","volume":"28","author":"Starchenko","year":"2017","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2026.218607_bib81","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218607_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229077","article-title":"Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer","volume":"15","author":"Nair","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218607_bib83","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1073\/pnas.1821442116","article-title":"Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope","volume":"116","author":"Orellana","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218607_bib84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccell.2018.06.006","article-title":"Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development","volume":"34","author":"Binder","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218607_bib85","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1541-7786.MCR-15-0477","article-title":"A novel EGFR extracellular domain mutant, EGFR\u0394768, possesses distinct biological and biochemical properties in Neuroblastoma","volume":"14","author":"Keller","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib86","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.2147\/OTT.S131999","article-title":"The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive","volume":"10","author":"Yu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2026.218607_bib87","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/0008-5472.CAN-16-0754","article-title":"Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism","volume":"77","author":"Braig","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.620256","article-title":"EGFR alterations influence the cetuximab treatment response and c-MET tyrosine-kinase inhibitor sensitivity in experimental head and neck squamous cell carcinomas","volume":"27","author":"Nelh\u0171bel","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.canlet.2026.218607_bib89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"Bertotti","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218607_bib90","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdv005","article-title":"Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment","volume":"26","author":"Morelli","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib91","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1038\/s41467-025-59588-3","article-title":"Ligand-activated EGFR\/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer","volume":"16","author":"Qu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218607_bib92","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1200\/JCO.2005.03.0536","article-title":"Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent Colorectal adenocarcinoma","volume":"23","author":"Rothenberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib93","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.bjc.6603055","article-title":"Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer","volume":"94","author":"Townsley","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218607_bib94","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/cancers15030629","article-title":"Treatment strategies for non-small cell lung cancer with common EGFR mutations: a review of the history of EGFR TKIs approval and emerging data","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218607_bib95","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer","volume":"16","author":"Tan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib96","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1078-0432.CCR-22-3094","article-title":"A phase Ib\/II trial of combined BRAF and EGFR inhibition in BRAF V600E positive metastatic colorectal cancer and other cancers: the EVICT (erlotinib and vemurafenib in combination trial) Study","volume":"29","author":"Tan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib97","article-title":"L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: comparison of osimertinib vs. cetuximab","volume":"4","author":"Marrocco","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ady4877","article-title":"Single\u2013amino acid variants in target epitopes can confer resistance to antibody-based therapies","volume":"17","author":"Marone","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib99","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/cam4.4939","article-title":"Distribution and favorable prognostic implication of genomic EGFR alterations in IDH \u2010wildtype glioblastoma","volume":"12","author":"Higa","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218607_bib100","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.biochem.2c00384","article-title":"Identification of activating mutations in the transmembrane and extracellular domains of EGFR","volume":"61","author":"Wagner","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2026.218607_bib101","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-15-2400","article-title":"The first-in-class Anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer","volume":"22","author":"S\u00e1nchez-Mart\u00edn","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib102","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","article-title":"Molecular mechanisms underlying ErbB2\/HER2 action in breast cancer","volume":"19","author":"Harari","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218607_bib103","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/emboj\/17.12.3385","article-title":"Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers","volume":"17","author":"Lenferink","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218607_bib104","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1200\/JCO.2008.21.3744","article-title":"Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab","volume":"27","author":"Jacobs","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib105","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1158\/1078-0432.CCR-23-0859","article-title":"Associations between AI-Assisted tumor Amphiregulin and Epiregulin IHC and outcomes from Anti-EGFR therapy in the routine management of metastatic colorectal cancer","volume":"29","author":"Williams","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib106","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1158\/0008-5472.CAN-25-0073","article-title":"AREG and EREG are predictive biomarkers of response to EGFR inhibition in gastroesophageal cancer","volume":"85","author":"Conticelli","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218607_bib107","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1111\/cas.14526","article-title":"Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer","volume":"111","author":"Hong","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218607_bib108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib109","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013Mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib110","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218607_bib112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013Mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218607_bib113","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:05:31Z","timestamp":1783199131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526003708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":112,"alternative-id":["S0304383526003708"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218607","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218607"}}